Skip to main content

Table 7 Chromosomal locations showing different frequencies of aberration between the two groups in lymph node positive patients

From: Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer

 

Recurrence group (N = 7)

Non-recurrence group (n = 13)

Adjusted p value

 

Aberration

No aberration

Aberration

No aberration

 

1p36.33-1p35.3 loss

3

4

0

13

0.052

4q13.1-4q34.3 loss

0

7

7

6

0.052

11p15.5-11p15.4 loss

4

3

1

12

0.052

19q12-19q13.2 gain

0

7

8

5

0.052

8q21.13-8q24.22 gain

6

1

5

8

0.111

11p11.2-11p11.12 loss

4

3

2

11

0.112

17p13.3-17p11.2 loss

3

4

1

12

0.113

7p21.2-7p13 gain

3

4

2

11

0.286

11q14.3-11q24.3 loss

4

3

4

9

0.326

17q23.2-17q24.2 gain

3

4

9

4

0.326

20q13.13-20q13.33 gain

3

4

3

10

0.421

1q32.1-1q44 gain

6

1

9

4

0.451